Key statistics
On Monday, Rhythm Pharmaceuticals Inc (RYTM:NMQ) closed at 94.94, -22.31% below its 52-week high of 122.20, set on Dec 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 90.19 |
|---|---|
| High | 96.00 |
| Low | 88.49 |
| Bid | 88.00 |
| Offer | 95.15 |
| Previous close | 92.73 |
| Average volume | 800.53k |
|---|---|
| Shares outstanding | 68.29m |
| Free float | 63.64m |
| P/E (TTM) | -- |
| Market cap | 6.33bn USD |
| EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
- Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
- Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
- Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
- Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
- Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
- Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
More ▼
